98%
921
2 minutes
20
Background: Little is known about the long-term (>2 years) relationship between the time-varying drug adherence and healthcare utilization for patients with diabetes.
Objective: To characterize the relationship between time-varying anti-hyperglycemic medication adherence and healthcare utilization in patients with diabetes, using data from Alberta's Tomorrow Project, a population-based cohort study in Alberta, Canada.
Methods: Incident cases of diabetes with at least 24 months of follow-up were included in the study. Anti-hyperglycemic drug adherence was measured by proportion of days covered (PDC) in the past 12 months for each year after diagnosis. The rate of healthcare utilization was assessed for the subsequent 12 months, 36 months and 60 months. A time-varying, negative binomial generalized estimating equation model was used to examine the association between medication adherence and healthcare utilization.
Results: Among 2155 incident cases of diabetes, average age at diagnosis was 59.6±9.3, 51.0% were female and average duration of follow-up was 7.3±3.7 (range, 2.0-16.2) years. The proportion of patients taking anti-hyperglycemic medications was 47.6% during the first year of diagnosis, which increased to 77.3% by the end of follow-up. Compared to adherent patients (PDC≥0.8), non-adherent patients (PDC<0.8) had substantially higher rate of all-cause hospitalization [incident rate ratio, IRR=1.48 (1.22-1.79), ED visits [1.30 (1.15-1.47)] and GP visits [1.17 (1.08-1.27)] in the subsequent 12 months. However, these associations became weaker with longer follow-up [eg, IRR=1.18 (0.98-1.39) and 1.05 (0.94-1.18) for all-cause hospitalization in the subsequent 36 and 60 months, respectively].
Conclusion: Poor adherence among diabetic patients was associated with substantially higher rate of healthcare utilization in the short term (eg, 12 months); however, this association weakened over a longer period (eg, 36-60 months).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199902 | PMC |
http://dx.doi.org/10.2147/PPA.S362539 | DOI Listing |
AIDS Behav
September 2025
New York University School of Global Public Health, New York, NY, USA.
We developed and implemented a PrEP navigation program ("SNAPS") in a NYC safety-net hospital with the objectives to co-locate navigation, clinical PrEP services, and payment assistance. Adherence and retention to PrEP-related care were assessed by mean medication possession ratios (MPRs) and number of appointments over 12 months. Compared to the pre-SNAPS cohort, the post-SNAPS cohort was less likely to be cisgender male (64.
View Article and Find Full Text PDFDiabetes Metab Syndr Obes
August 2025
Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, 51452, Saudi Arabia.
Purpose: Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors represent major advancements in the management of type 2 diabetes. However, many patients remain suboptimally managed with these therapies. This underutilization highlights the need for practical implementation strategies in real-world settings.
View Article and Find Full Text PDFCardiovasc Ther
September 2025
Department of Cardiology, Tianjin University Chest Hospital, Tianjin, China.
Hypertension constitutes a major risk factor for cardiovascular diseases. Globally, the management and control of hypertension remain suboptimal. At present, pharmacological intervention is a critical strategy for patients with hypertension to achieve blood pressure regulation.
View Article and Find Full Text PDFNepal J Epidemiol
September 2025
Sir Seewoosagur Ramgoolam Medical College, Belle Rive, Mauritius.
Background: Arthritis affects millions of people worldwide; however, its mismanagement remains a growing global challenge, resulting in reduced quality of life (QoL) and disability. Digital health (DH), including smartphones, could be the key to solving this problem. Specific evidence-based reviews on the use of DH in this context are lacking.
View Article and Find Full Text PDFCureus
August 2025
Scientific Services, USV Private Limited, Mumbai, IND.
Background Medication adherence is mostly influenced by cost, and disease management can be achieved through cost-effective combinations. The present study aimed to evaluate adherence to the cost-effective fixed dose combination (FDC) of rosuvastatin and clopidogrel in the management of cardiovascular diseases (CVD). Methods This retrospective, non-randomized, non-comparative, multicenter study was conducted across 100 healthcare centers in India.
View Article and Find Full Text PDF